Cargando…

Randomized phase III study of daratumumab versus bortezomib plus daratumumab as maintenance therapy after D-MPB for transplant-ineligible patients with untreated multiple myeloma (JCOG1911, B-DASH study)

Daratumumab, melphalan, prednisolone and bortezomib followed by daratumumab maintenance is a standard regimen for transplant-ineligible newly diagnosed multiple myeloma. A large-scale clinical trial demonstrated that progression-free survival declined more sharply during the maintenance phase than d...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Tomotaka, Terada, Mitsumi, Machida, Ryunosuke, Kataoka, Tomoko, Ito, Yuta, Kataoka, Keisuke, Maruyama, Dai, Nagai, Hirokazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10064323/
http://dx.doi.org/10.1093/jjco/hyac198